396 related articles for article (PubMed ID: 19251630)
1. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis.
Hugonnet JE; Tremblay LW; Boshoff HI; Barry CE; Blanchard JS
Science; 2009 Feb; 323(5918):1215-8. PubMed ID: 19251630
[TBL] [Abstract][Full Text] [Related]
2. Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC lead to clavulanate resistance?: a biochemical rationale for the use of β-lactam-β-lactamase inhibitor combinations.
Kurz SG; Wolff KA; Hazra S; Bethel CR; Hujer AM; Smith KM; Xu Y; Tremblay LW; Blanchard JS; Nguyen L; Bonomo RA
Antimicrob Agents Chemother; 2013 Dec; 57(12):6085-96. PubMed ID: 24060876
[TBL] [Abstract][Full Text] [Related]
3. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates.
Zhang D; Wang Y; Lu J; Pang Y
Antimicrob Agents Chemother; 2016 Jan; 60(1):393-9. PubMed ID: 26525785
[TBL] [Abstract][Full Text] [Related]
5. Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics.
Cohen KA; El-Hay T; Wyres KL; Weissbrod O; Munsamy V; Yanover C; Aharonov R; Shaham O; Conway TC; Goldschmidt Y; Bishai WR; Pym AS
EBioMedicine; 2016 Jul; 9():170-179. PubMed ID: 27333036
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial active-site variants confer sustained clavulanate resistance in BlaC β-lactamase from Mycobacterium tuberculosis.
Egesborg P; Carlettini H; Volpato JP; Doucet N
Protein Sci; 2015 Apr; 24(4):534-44. PubMed ID: 25492589
[TBL] [Abstract][Full Text] [Related]
7. Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate.
Gonzalo X; Drobniewski F
J Antimicrob Chemother; 2013 Feb; 68(2):366-9. PubMed ID: 23070734
[TBL] [Abstract][Full Text] [Related]
8. [
Shi J; Zheng DW; Ma XG; Su RY; Zhu YK; Wang SH; Chang WJ; Sun GQ; Sun DY
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Aug; 46(8):797-805. PubMed ID: 37536990
[No Abstract] [Full Text] [Related]
9. New Conformations of Acylation Adducts of Inhibitors of β-Lactamase from Mycobacterium tuberculosis.
Tassoni R; Blok A; Pannu NS; Ubbink M
Biochemistry; 2019 Feb; 58(7):997-1009. PubMed ID: 30632739
[TBL] [Abstract][Full Text] [Related]
10. Structure of the covalent adduct formed between Mycobacterium tuberculosis beta-lactamase and clavulanate.
Tremblay LW; Hugonnet JE; Blanchard JS
Biochemistry; 2008 May; 47(19):5312-6. PubMed ID: 18422342
[TBL] [Abstract][Full Text] [Related]
11. Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate.
Hugonnet JE; Blanchard JS
Biochemistry; 2007 Oct; 46(43):11998-2004. PubMed ID: 17915954
[TBL] [Abstract][Full Text] [Related]
12. Kinetic and Structural Characterization of the Interaction of 6-Methylidene Penem 2 with the β-Lactamase from Mycobacterium tuberculosis.
Hazra S; Kurz SG; Wolff K; Nguyen L; Bonomo RA; Blanchard JS
Biochemistry; 2015 Sep; 54(36):5657-64. PubMed ID: 26237118
[TBL] [Abstract][Full Text] [Related]
13. Durlobactam, a Diazabicyclooctane β-Lactamase Inhibitor, Inhibits BlaC and Peptidoglycan Transpeptidases of
Nantongo M; Nguyen DC; Bethel CR; Taracila MA; Li Q; Dousa KM; Shin E; Kurz SG; Nguyen L; Kreiswirth BN; Boom WH; Plummer MS; Bonomo RA
ACS Infect Dis; 2024 May; 10(5):1767-1779. PubMed ID: 38619138
[TBL] [Abstract][Full Text] [Related]
14. Hydrolysis of clavulanate by Mycobacterium tuberculosis β-lactamase BlaC harboring a canonical SDN motif.
Soroka D; Li de la Sierra-Gallay I; Dubée V; Triboulet S; van Tilbeurgh H; Compain F; Ballell L; Barros D; Mainardi JL; Hugonnet JE; Arthur M
Antimicrob Agents Chemother; 2015 Sep; 59(9):5714-20. PubMed ID: 26149997
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of Mycobacterium tuberculosis l,d-transpeptidase LdtMt₁ by carbapenems and cephalosporins.
Dubée V; Triboulet S; Mainardi JL; Ethève-Quelquejeu M; Gutmann L; Marie A; Dubost L; Hugonnet JE; Arthur M
Antimicrob Agents Chemother; 2012 Aug; 56(8):4189-95. PubMed ID: 22615283
[TBL] [Abstract][Full Text] [Related]
16. Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
Cavanaugh JS; Jou R; Wu MH; Dalton T; Kurbatova E; Ershova J; Cegielski JP;
J Antimicrob Chemother; 2017 Jun; 72(6):1678-1687. PubMed ID: 28333192
[TBL] [Abstract][Full Text] [Related]
17. In vitro cross-linking of Mycobacterium tuberculosis peptidoglycan by L,D-transpeptidases and inactivation of these enzymes by carbapenems.
Cordillot M; Dubée V; Triboulet S; Dubost L; Marie A; Hugonnet JE; Arthur M; Mainardi JL
Antimicrob Agents Chemother; 2013 Dec; 57(12):5940-5. PubMed ID: 24041897
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis.
Solapure S; Dinesh N; Shandil R; Ramachandran V; Sharma S; Bhattacharjee D; Ganguly S; Reddy J; Ahuja V; Panduga V; Parab M; Vishwas KG; Kumar N; Balganesh M; Balasubramanian V
Antimicrob Agents Chemother; 2013 Jun; 57(6):2506-10. PubMed ID: 23507276
[TBL] [Abstract][Full Text] [Related]
19. The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis.
Dinçer I; Ergin A; Kocagöz T
Int J Antimicrob Agents; 2004 Apr; 23(4):408-11. PubMed ID: 15081094
[TBL] [Abstract][Full Text] [Related]
20. Meropenem-clavulanate: a new strategy for the treatment of tuberculosis?
Holzgrabe U
ChemMedChem; 2009 Jul; 4(7):1051-3. PubMed ID: 19462395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
